Abstract: Disclosed herein is an adeno-associated virus (AAV) particle comprising a surface-bound peptide that enhances transduction of cells across the blood-brain barrier (BBB). Also disclosed herein is a modified AAV capsid protein comprising an insertion of a polypeptide that enhances transduction of cells across the BBB, and an AAV particle comprising the modified AAV capsid protein. Specific peptides are provided. Pharmaceutical formulations and method of administering/delivering a nucleic acid to a cell of the brain and/or central nervous system are also disclosed.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
February 20, 2024
Assignee:
The University of North Carolina at Chapel Hill
Abstract: A composition for increasing vaccine yields due to increased virus growth in mutation comprising a vaccine strain bearing the Y161F mutation in hemagglutinin (HA). Y161F in HA increases HA thermostability without changing its original antigenic properties and enhances its binding affinity in the vaccine production platforms used in influenza vaccine manufacturing. A method for optimizing preparation of influenza vaccine seed strains which can further lower the cost of vaccines and increase profits for the vaccine companies, and also maintain antigenic stability during vaccine deliveries.
Abstract: Provided herein are an interleukin-2 polypeptide and a fusion protein thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
Type:
Grant
Filed:
April 27, 2021
Date of Patent:
February 13, 2024
Assignee:
Anwita Biosciences, Inc.
Inventors:
Fan Ye, Eric Liao, Ella Li, Matthew Siegel, Jianing Huang, Ziyang Zhong
Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of the novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.
Type:
Grant
Filed:
November 11, 2021
Date of Patent:
February 6, 2024
Assignee:
NovoBiotic Pharmaceuticals, LLC
Inventors:
Dallas Hughes, Amy Spoering, Aaron J. Peoples, Losee Lucy Ling, Anthony Nitti, William Millett, Ashley Zullo, Kim Lewis, Slava Epstein, Alysha Desrosiers, Catherine Achorn, Kelly Demeo
Abstract: The present disclosure pertains to a process for manufacturing ethyleneamine compounds selected from the group of ethyleneamines and hydroxyethylethyleneamines wherein the process comprises two reaction sequences.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
January 30, 2024
Assignee:
NOURYON CHEMICALS INTERNATIONAL B.V.
Inventors:
Rolf Krister Edvinsson, Antoon Jacob Berend Ten Kate, Michiel Jozef Thomas Raaijmakers, Rens Veneman, Slavisa Jovic, Lawien Feisal Zubeir, Eike Nicolas Kantzer, Ina Ehlers, Hendrik Van Dam, Karl Fredrik Lake
Abstract: Disclosed are methods of decreasing cachexia in a subject comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof. Disclosed are methods of decreasing bone destruction in a subject comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof. Disclosed are methods of ameliorating one or more symptoms or side effects of breast or prostate cancer in a breast or prostate cancer patient comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof. Disclosed are methods of treating osteoporosis in a subject comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof.
Type:
Grant
Filed:
October 22, 2020
Date of Patent:
January 30, 2024
Assignee:
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Abstract: The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.
Abstract: The present invention provides to compositions and methods useful in the treatment of neurological disorders including, but not limited to, Angelman syndrome, depression, traumatic brain injury, stroke, and Alzheimer's disease. CN2097, a rationally designed cyclic peptidomimetic drug that has been demonstrated to have effectiveness in preclinical models for the treatment of neurological disorders, is rapidly cleared and has a short half-life. The present invention provides a stable analog of CN2097.
Abstract: Process for manufacturing ethyleneamine compounds selected from the group of ethyleneamines and hydroxyethylethyleneamines wherein the process comprises two reaction sequences.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
January 23, 2024
Assignee:
NOURYON CHEMICALS INTERNATIONAL B.V.
Inventors:
Antoon Jacob Berend Ten Kate, Rolf Krister Edvinsson, Michiel Jozef Thomas Raaijmakers, Rens Veneman, Slavisa Jovic, Lawien Zubeir, Eike Nicolas Kantzer, Ina Ehlers, Hendrik Van Dam, Karl Fredrik Lake
Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
Abstract: Disclosed herein are transfection complexes comprising at least one cell surface ligand; at least one helper lipid component; and a transfection enhancer. Also disclosed are pharmaceutical compositions comprising the disclosed transfection complexes, and a pharmaceutically acceptable carrier. Further, disclosed are methods of transfecting a cell, the method comprising the steps of: obtaining a transfection complex as disclosed; and contacting a cell with the transfection complex.
Abstract: The present disclosure relates to relates methods and associated compositions that provide fast, efficient site-selective conjugation of a protein, such as the pore-forming protein ?-hemolysin, to a biomolecule, such as a DNA polymerase, and the use of such site-selective protein-biomolecule conjugates in nanopore devices and methods.
Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
Abstract: The present invention provides a composition comprising the compound having the structure: or a salt of the compound; 4-amino-2-[19F]-fluorobenzoic acid or a salt of 4-amino-2-[19F]-fluorobenzoic acid; and at least one acceptable carrier.
Type:
Grant
Filed:
September 6, 2017
Date of Patent:
January 2, 2024
Assignee:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Inventors:
Peter Tonge, Zhuo Zhang, Peter Smith-Jones, Li Liu, Hui Wang
Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.
Type:
Grant
Filed:
May 25, 2021
Date of Patent:
January 2, 2024
Assignee:
EMORY UNIVERSITY
Inventors:
Raymond F Schinazi, Franck Amblard, Ladislau Kovari, Peng Liu, Shaoman Zhou, Benjamin D Kuiper, BRadley J Keusch
Abstract: Methods and uses of activators of the APC complex for treating cancer in a subject, inhibiting the growth of a cancer cell, increasing sensitivity to a cancer treatment in a cancer cell or a subject and/or reducing resistance to a cancer treatment in a cancer cell or a subject.
Abstract: A two-step one-pot process for reacting glycolaldehyde with an aminating agent in the presence of a reactive organic fluid for instance a reactive solvent is provided. The first step comprises of contacting glycolaldehyde with an aminating agent in the presence of a reactive fluid for instance a reactive solvent under inert atmosphere to produce unsaturated intermediates, and reacting the reaction mixture obtained in step 1 with hydrogen in the presence of a supported hydrogenation catalyst in a second step.
Type:
Grant
Filed:
April 4, 2019
Date of Patent:
December 26, 2023
Inventors:
Michiel Jules Y Pelckmans, William Hendrick Faveere, Bert Sels
Abstract: The present invention relates to pharmaceutical aerosols comprising a ?-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity.
Type:
Grant
Filed:
October 6, 2021
Date of Patent:
December 19, 2023
Assignee:
POLYPHOR AG
Inventors:
Christian Ludin, Manfred Keller, Piet Bruijnzeel, Johann Zimmermann, Philip Barth, Eric Chevalier